EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Estrogen and cardiovascular disease

Felice Gersh, James H O'Keefe, Andrew Elagizi, Carl J Lavie, Jari A Laukkanen

Progress in Cardiovascular Diseases · 2024-01

DOI: 10.1016/j.pcad.2024.01.015 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Progress in Cardiovascular Diseases, 2024-01. Verfasst von Felice Gersh und 4 weiteren Autor:innen. Beteiligte Einrichtung: University of Arizona School of Medicine, Division of Integrative Medicine, Tucson, AZ, USA. Electronic address: fgersh@integrativemgi.com. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Estrogen Replacement Therapy, Estrogens. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 67 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A large body of scientific research accumulated over the past twenty years documents the cardiovascular (CV) benefits of estradiol (E2) and progesterone (P4) in reproductive aged women. In contrast, accelerated development of CV disease (CVD) occurs in the absence of ovarian produced E2 and P4. Hormone replacement therapy (HRT) with E2 and P4 has been shown to cause no harm to younger menopausal women. This robust scientific data supports a reconsideration of the prescriptive use of E2 and P4 as preventative therapeutics for the reduction of CVD, even without additional large-scale studies of the magnitude of the Women's Health Initiative (WHI). With the current expanded understanding of the critical modulatory role played by E2 on a multitude of systems and enzymes impacting CVD onset, initiation of HRT shortly after cessation of ovarian function, known as the "Timing Hypothesis", should be considered to delay CVD in recently postmenopausal women.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesEstrogen Replacement TherapyEstrogensHumansFemaleHeart Disease Risk FactorsProgesteroneEstradiolWomen's HealthRisk AssessmentMenopauseCardiovascular SystemProtective FactorsRisk Factors

Stichwörter der Autor:innen

Cardiovascular diseaseEstrogenHormone replacement therapyMenopauseWomen

Substanzen

EstrogensProgesteroneEstradiol

Autor:innen und Institutionen

  • University of Arizona School of Medicine, Division of Integrative Medicine, Tucson, AZ, USA. Electronic address: fgersh@integrativemgi.com.
  • Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City, Kansas City, MO, USA.
  • John Ochsner Heart and Vascular Institute, Ochsner Clinical School -the University of Queensland School of Medicine, New Orleans, LA, USA.
  • Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland; Department of Internal Medicine, Wellbeing Services County of Central Finland, Jyvaskyla, Finland.

Zitieren

APA

Gersh, F., O'Keefe, J. H., Elagizi, A., Lavie, C. J., & Laukkanen, J. A. (2024). Estrogen and cardiovascular disease. Progress in Cardiovascular Diseases. https://doi.org/10.1016/j.pcad.2024.01.015

Vancouver

Gersh F, O'Keefe JH, Elagizi A, Lavie CJ, Laukkanen JA. Estrogen and cardiovascular disease. Progress in Cardiovascular Diseases. 2024. doi:10.1016/j.pcad.2024.01.015

BibTeX
@article{Gersh2024,
  author = {Gersh, Felice and O'Keefe, James H and Elagizi, Andrew and Lavie, Carl J and Laukkanen, Jari A},
  title = {Estrogen and cardiovascular disease},
  journal = {Progress in Cardiovascular Diseases},
  year = {2024},
  doi = {10.1016/j.pcad.2024.01.015}
}
Kostenlos starten →